Cargando…

Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis

Gefitinib is a potent inhibitor of EGFR and represents the front-line treatment for non-small cell lung cancer (NSCLC) therapeutics. However, NSCLC patients are prone to develop acquired resistance through as yet, undefined mechanisms of resistance. Here, we investigated the role of COX-2 during gef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Qin-fang, Fang, Qi-yu, Ji, Xian-Xiu, Zhou, Song-wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150449/ https://www.ncbi.nlm.nih.gov/pubmed/32284763 http://dx.doi.org/10.7150/jca.42850

Ejemplares similares

LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
por: Ding, Jianghua, et al.
Publicado: (2022)

Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations
por: Choi, Seul-Ki, et al.
Publicado: (2022)

Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Zhu, Xinhai, et al.
Publicado: (2016)

SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020)

Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR‐PI3K‐AKT‐mTOR signalling pathway
por: Fu, Xiao, et al.
Publicado: (2019)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
por: Yu, Yaya, et al.
Publicado: (2023)

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
por: Han, Shuyan, et al.
Publicado: (2023)

Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
por: Wang, Bing, et al.
Publicado: (2017)

Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage
por: Peng, Minghui, et al.
Publicado: (2022)

Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway
por: Chen, Shu-yi, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
por: ZHAO, ZHONG-QUAN, et al.
Publicado: (2016)

SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals
por: She, Kelin, et al.
Publicado: (2019)

miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR
por: Ma, Hui-Ping, et al.
Publicado: (2019)

Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Liu, Pengfei, et al.
Publicado: (2019)

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
por: Li, Hongyu, et al.
Publicado: (2015)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis
por: Kang, Xiao-Hong, et al.
Publicado: (2013)

MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway
por: Jiang, Jingjin, et al.
Publicado: (2016)

RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma
por: Gao, Fangyan, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

FGFRL1 affects chemoresistance of small‐cell lung cancer by modulating the PI3K/Akt pathway via ENO1
por: Chen, Rui, et al.
Publicado: (2020)

MLL4 Regulates the Progression of Non–Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis
por: Yang, Yang, et al.
Publicado: (2023)

GPX2 promotes EMT and metastasis in non‐small cell lung cancer by activating PI3K/AKT/mTOR/Snail signaling axis
por: Peng, Fang, et al.
Publicado: (2023)

Novel Biphasic Role of Resolvin D1 on Expression of Cyclooxygenase-2 in Lipopolysaccharide-Stimulated Lung Fibroblasts Is Partly through PI3K/AKT and ERK2 Pathways
por: Wu, Derong, et al.
Publicado: (2013)

JMJD8 Promotes Malignant Progression of Lung Cancer by Maintaining EGFR Stability and EGFR/PI3K/AKT Pathway Activation
por: Zhang, Bo, et al.
Publicado: (2021)

p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling
por: Zhang, Yize, et al.
Publicado: (2019)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR/PI3K/AKT Signaling Pathway
por: Cao, Shengya, et al.
Publicado: (2020)

Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation
por: Chang, Tung-Cheng, et al.
Publicado: (2018)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

Gefitinib-coated balloon inhibits the excessive hyperplasia of intima after vascular injuries through PI3K/AKT pathway
por: Tang, Fen, et al.
Publicado: (2019)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma
por: Zhang, Jiale, et al.
Publicado: (2018)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
por: Wang, Fei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0bs151o20fvj5o2p103nvbl991